Newswise Feature Channel: Cancer

Increasing Chemotherapy Effectiveness with Oleanolic Acid from Grapes

Sbarro Health Research Organization (SHRO) — Fri, 27 Dec 2024 18:00:35 EST

Researchers describe a new potential role for Oleanolic Acid as a modulator of the DNA damage response following Camptothecin treatment. Administration of Oleanolic Acid in combination with Camptothecin for cancer chemotherapy may reduce the amount of drug needed and increase the effectiveness of treatment.

Interplay and Therapeutic Implications of Colorectal Cancer Stem Cells, Tumor Microenvironment, and Gut Microbiota

World Journal of Stem Cells — Thu, 26 Dec 2024 12:00:54 EST

This article discusses the interplay between colorectal cancer (CRC) stem cells, tumor microenvironment (TME), and gut microbiota, emphasizing their dynamic roles in cancer progression and treatment resistance. It highlights the adaptabilit

Switching Off Drug-Resistant Cancer

National Institute of Biomedical Imaging and Bioengineering — Mon, 23 Dec 2024 19:05:09 EST

Genetic diversity is key to survival in an everchanging environment. Cancer cells -- thanks to their abundant and eclectic mix of mutations -- unfortunately excel at surviving. Drug treatments can diminish tumors for a time but, in many cases, give rise to resistant cells. A different drug may eliminate the resistant population during follow-up treatment only to leave behind a new resistant line that continues to proliferate.

Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

Perelman School of Medicine at the University of Pennsylvania — Mon, 23 Dec 2024 18:30:34 EST

UTSW Scientists Identify Cancer-Suppressing Genetic Mutation

UT Southwestern Medical Center — Mon, 23 Dec 2024 17:15:43 EST

UT Southwestern Medical Center researchers identified a genetic mutation that slows the growth of melanoma and potentially other cancers by harnessing the power of the immune system. Their findings, published in the Journal of Experimental Medicine, could lead to new treatments that improve outcomes from existing cancer immunotherapies.

UC Davis Researchers Help Decode the Cause of Aggressive Breast Cancer in Women of Color

UC Davis Health — Fri, 20 Dec 2024 17:55:13 EST

Cancer center researchers may have uncovered the specific biomarker that causes Black women to get triple-negative breast cancer at higher rates than other women.

Expert Available to Discuss Report to Inform Dietary Guidelines Finding Mixed Health Outcomes Associated with Moderate Alcohol Consumption

University of Idaho — Fri, 20 Dec 2024 17:50:38 EST

The Secret Life of ALAS1: How a Basic Science Discovery Could Pave the Way for Better siRNA Therapies

Memorial Sloan Kettering Cancer Center — Fri, 20 Dec 2024 17:30:12 EST

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.

The Neiman Imaging Comorbidity Index Proves Effective for Risk-Adjustment Across Medicare, Medicaid and Privately Insured Populations

Harvey L. Neiman Health Policy Institute — Fri, 20 Dec 2024 16:55:00 EST

Previously in 2024, researchers at the Harvey L. Neiman Health Policy Institute published a novel risk-adjustment score--the Neiman Imaging Comorbidity Index (NICI)--predictive of patients' advanced imaging use. Now, these researchers have published more extensive validation of the NICI to test its utility in datasets other than the claims dataset from which it was developed.

Automation of Nuclear Chemistry Processes Leads to More Efficient Production of Astatine for Cancer Therapy

Department of Energy, Office of Science — Fri, 20 Dec 2024 14:45:26 EST

Astatine-211 (At-211) is a promising alpha emitting radioisotope for cancer therapy, but its short 7.2-hour half-life means that it must be handled quickly to minimize losses due to radioactive decay. In this research, scientists designed and tested an automated device for producing At-211 that improves production time and efficiency. The device also minimizes the dose of radioactivity to production staff and reduces the time needed to prepare samples for shipment.

Building a Multilayered Drug Delivery System That's Activated by Ultrasound

National Institute of Biomedical Imaging and Bioengineering — Fri, 20 Dec 2024 09:35:35 EST

Releasing a drug selectively in specific locations in the body, including the brain, has been challenging. Researchers at the University of Utah have tackled the problem by designing ultrasound-sensitive nanoparticles that release a drug at the targeted site when activated by focused ultrasound.

Driving Innovation in Epigenetics: EpiCypher's 2024 Impact in Chromatin Research

EpiCypher, Inc. — Fri, 20 Dec 2024 09:10:17 EST

A Steady Hand Close To Home - There's No Better Gift

Hackensack Meridian Health — Thu, 19 Dec 2024 21:30:38 EST

The world-class Center for Microsurgery and Complex Reconstruction at Hackensack University Medical Center is changing lives.

Lanza Named Fellow of National Academy of Inventors

Washington University in St. Louis — Thu, 19 Dec 2024 20:45:05 EST

Gregory Lanza, MD, PhD, the James R. Hornsby Family Professor in Biomedical Sciences in the John T. Milliken Department of Medicine at WashU Medicine, has been named a fellow of the National Academy of Inventors (NAI) in recognition of his application of nanotechnology to a broad variety of medical innovations.

A New Platform to Help People with Rare Cancers

Universite de Montreal — Thu, 19 Dec 2024 19:10:23 EST

Marie-Pascale Pomey receives $200,000 in funding to create a platform to help people with rare cancers find reliable information and navigate the healthcare system.

Hematology, Oncology, Neuro-Oncology Stem Cell Transplantation Updates: Winter 2024

Ann and Robert H. Lurie Children's Hospital of Chicago — Thu, 19 Dec 2024 09:00:13 EST

"We will use optical genome mapping for molecular diagnosis of brain tumors, which is a new application of this technology specifically designed to detect structural variants, meaning large chan...

GenomOncology Appoints Dr. Jack Lord to Board of Directors

GenomOncology — Thu, 19 Dec 2024 08:10:11 EST

GenomOncology is proud to announce the appointment of Dr. Jonathan "Jack" Lord, M.D., to its Board of Directors. A nationally recognized leader in healthcare innovation, Dr. Lord brings a wealth of expertise in driving change through new technologies and therapies, making him an ideal fit for GenomOncology's mission to advance precision medicine in oncology.

MD Anderson Research Highlights for December 18, 2024

University of Texas MD Anderson Cancer Center — Wed, 18 Dec 2024 22:15:07 EST

The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Researchers Find New Way to 'Starve' Prostate Cancer Tumors at the Cellular Level

Indiana University — Wed, 18 Dec 2024 20:25:01 EST

New research has uncovered a novel vulnerability in prostate cancer animal models that starves prostate tumors of critical nutrients and stunts their growth, which could lead to the development of new treatments for the deadly disease.

Roswell Park Team Discovers New Treatment Target for Neuroendocrine Prostate Cancer

Roswell Park Comprehensive Cancer Center — Wed, 18 Dec 2024 20:05:13 EST

A team of researchers at Roswell Park , led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer. Their findings, newly published in the journal Oncogene, suggest that a set of processes known as the mitochondrial unfolded protein response, could be an Achilles' heel for this often-deadly cancer type, and may point the way to a new treatment approach.